US Patent 11338013 Combination therapy for C3 inhibition
Patent 11338013 was granted and assigned to Apellis Pharmaceuticals on May, 2022 by the United States Patent and Trademark Office.
Is a
Current Assignee
Date Filed
October 16, 2017
Date of Patent
May 24, 2022
Patent Application Number
16342477
Patent Jurisdiction
Patent Number
Patent Primary Examiner
Find more entities like US Patent 11338013 Combination therapy for C3 inhibition
Use the Golden Query Tool to find similar entities by any field in the Knowledge Graph, including industry, location, and more.
By using this site, you agree to our Terms of Service.